The specificity of the NPC1L1 pathway, the extent to which its inhibition contributes to NAFLD protection, and the precise mechanisms through which CTS modulates liver lipid metabolism through NPC1L1 inhibition all require further clarification. Here, NPC1L1 is linked to metabolic dysfunction-associated steatotic liver disease.